- Home
- CODX vs BGLC Comparison
CODX vs BGLC Comparison
Compare CODX & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODX
- BGLC
- Stock Information
- Founded
- CODX 2013
- BGLC 2017
- Country
- CODX United States
- BGLC Malaysia
- Employees
- CODX N/A
- BGLC N/A
- Industry
- CODX Medical/Dental Instruments
- BGLC Medical Specialities
- Sector
- CODX Health Care
- BGLC Health Care
- Exchange
- CODX Nasdaq
- BGLC Nasdaq
- Market Cap
- CODX 9.8M
- BGLC 10.4M
- IPO Year
- CODX 2017
- BGLC N/A
- Fundamental
- Price
- CODX $0.31
- BGLC $5.69
- Analyst Decision
- CODX Buy
- BGLC
- Analyst Count
- CODX 2
- BGLC 0
- Target Price
- CODX $5.50
- BGLC N/A
- AVG Volume (30 Days)
- CODX 5.2M
- BGLC 53.3K
- Earning Date
- CODX 08-14-2025
- BGLC 08-18-2025
- Dividend Yield
- CODX N/A
- BGLC N/A
- EPS Growth
- CODX N/A
- BGLC N/A
- EPS
- CODX N/A
- BGLC N/A
- Revenue
- CODX $1,003,653.00
- BGLC $9,551,559.00
- Revenue This Year
- CODX N/A
- BGLC N/A
- Revenue Next Year
- CODX $31.58
- BGLC N/A
- P/E Ratio
- CODX N/A
- BGLC N/A
- Revenue Growth
- CODX N/A
- BGLC 4.01
- 52 Week Low
- CODX $0.23
- BGLC $2.01
- 52 Week High
- CODX $1.58
- BGLC $15.60
- Technical
- Relative Strength Index (RSI)
- CODX 53.94
- BGLC 52.93
- Support Level
- CODX $0.31
- BGLC $5.45
- Resistance Level
- CODX $0.35
- BGLC $5.79
- Average True Range (ATR)
- CODX 0.04
- BGLC 0.19
- MACD
- CODX 0.00
- BGLC -0.02
- Stochastic Oscillator
- CODX 35.36
- BGLC 82.35
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.